
STRO Stock Forecast & Price Target
STRO Analyst Ratings
Bulls say
Sutro Biopharma is a clinical-stage drug discovery and development company that manufactures next-generation protein therapeutics for the treatment of cancer and autoimmune disorders. The company's recent positive developments, including encouraging early data for its lead candidate STRO-004 and a favorable safety profile indicative of a differentiated therapeutic index, support a potentially broader clinical and commercial potential. The company's strong pipeline of other promising candidates, like STRO-006 and STRO-227, in addition to its strategic collaborations and robust cash position, position Sutro for long-term success and warrant a "Buy" rating.
Bears say
Sutro Biopharma is poised to benefit from its unique cell-free protein synthesis platform and diverse pipeline of drug candidates, but the company faces significant headwinds including fierce competition in the cancer therapeutics industry, regulatory and commercial risks, and potential need for additional financing in the future. They have demonstrated a strong financial position with a cash balance of $202.6M as of 1Q26, but their net loss has narrowed to $38.5M indicating continued financial challenges. Additionally, the safety profile of their key drug candidate STRO-004 appears to be weaker than that of its competitors.
This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
STRO Analyst Forecast & Price Prediction
Start investing in STRO
Order type
Buy in
Order amount
Est. shares
0 shares